MedTrace Logo

Major Activation Of NCC in Graft Urinary Exosomes

NCT03503461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2018-11-14

No results posted yet for this study

Summary

Hypertension is common disorder after renal transplantation and is associated with mortality. Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of hypertension, included in a "Gordon like" syndrome. However, prevalence of NCC activation by CNI is unknown. Our objective is to determine the prevalence of NCC activation three months after transplantation in patient treated by CNI.

Conditions

  • Kidney Transplantation

Interventions

OTHER

exosomes analysis

Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • France
  • Reunion

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03503461 on ClinicalTrials.gov